NCT07535359 2026-04-21
Medical Access Program for Ifinatamab Deruxtecan in 3L+ Pretreated Extensive-stage Small Cell Lung Cancer
Daiichi Sankyo
Available
Clinical Trials
7 trialsNCT07310277 2026-01-29
Expanded Access to ABBV-706
AbbVie
Available
NCT06064500 2025-03-10
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
Amgen
Approved for marketing
NCT04507919 2024-11-12
Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer
Novartis
No longer available
NCT04504513 2021-03-19
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer
G1 Therapeutics, Inc.
Approved for marketing
NCT04291937 2020-06-19
A Multicenter Expanded Access Treatment Protocol of Lurbinectedin in Previously Treated SCLC in the USA
Jazz Pharmaceuticals
Approved for marketing
NCT03503890 2019-09-10
Expanded Access to Rovalpituzumab Tesirine
AbbVie
No longer available